Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404

被引：0
|
作者：
Tadahiko Shien
Hiroji Iwata
Takashi Fukutomi
Kenichi Inoue
Kenjiro Aogi
Takayuki Kinoshita
Jiro Ando
Seiki Takashima
Kenichi Nakamura
Taro Shibata
Haruhiko Fukuda
机构：
[1] Okayama University Hospital,Department of Breast and Endocrine Surgery
[2] Aichi Cancer Center Hospital,Department of Breast Oncology
[3] National Cancer Center Hospital,Department of Breast Surgery
[4] Saitama Cancer Center,Department of Medical Oncology
[5] National Hospital Organization Shikoku Cancer Center,Department of Surgery
[6] Tochigi Cancer Center,Department of Breast Surgery
[7] National Cancer Center,JCOG Data Center, Multi
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 74卷
关键词：
Breast cancer; Adjuvant treatment; Node-positive; Premenopausal;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：603 / 609
页数：6
相关论文
共 30 条
  • [1] Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404
    Shien, Tadahiko
    Iwata, Hiroji
    Fukutomi, Takashi
    Inoue, Kenichi
    Aogi, Kenjiro
    Kinoshita, Takayuki
    Ando, Jiro
    Takashima, Seiki
    Nakamura, Kenichi
    Shibata, Taro
    Fukuda, Haruhiko
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (03) : 603 - 609
  • [2] Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401)
    Shien, Tadahiko
    Iwata, Hiroji
    Aogi, Kenjiro
    Fukutomi, Takashi
    Inoue, Kenichi
    Kinoshita, Takayuki
    Takahashi, Masato
    Matsui, Akira
    Shibata, Taro
    Fukuda, Haruhiko
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (06) : 982 - 988
  • [3] Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401)
    Tadahiko Shien
    Hiroji Iwata
    Kenjiro Aogi
    Takashi Fukutomi
    Kenichi Inoue
    Takayuki Kinoshita
    Masato Takahashi
    Akira Matsui
    Taro Shibata
    Haruhiko Fukuda
    [J]. International Journal of Clinical Oncology, 2014, 19 : 982 - 988
  • [4] Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy
    Toi, Masakazu
    Ikeda, Tadashi
    Akiyama, Futoshi
    Kurosumi, Masafumi
    Tsuda, Hitoshi
    Sakamoto, Goi
    Abe, Osahiko
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2007, 31 (04) : 899 - 906
  • [5] Erratum: Uracil-tegafur and tamoxifen versus cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in postoperative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study
    Y Park
    K Okamura
    S Mitsuyama
    T Saito
    J Koh
    S Kyono
    K Higaki
    M Ogita
    T Asaga
    H Inaji
    H Komichi
    N Kohno
    K Yamazaki
    F Tanaka
    T Ito
    H Nishikawa
    A Osaki
    H Koyama
    T Suzuki
    [J]. British Journal of Cancer, 2009, 101 : 1031 - 1031
  • [6] Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study
    Park, Y.
    Okamura, K.
    Mitsuyama, S.
    Saito, T.
    Koh, J.
    Kyono, S.
    Higaki, K.
    Ogita, M.
    Asaga, T.
    Inaji, H.
    Komichi, H.
    Kohno, N.
    Yamazaki, K.
    Tanaka, F.
    Ito, T.
    Nishikawa, H.
    Osaki, A.
    Koyama, H.
    Suzuki, T.
    [J]. BRITISH JOURNAL OF CANCER, 2009, 101 (04) : 598 - 604
  • [7] Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study
    Y Park
    K Okamura
    S Mitsuyama
    T Saito
    J Koh
    S Kyono
    K Higaki
    M Ogita
    T Asaga
    H Inaji
    H Komichi
    N Kohno
    K Yamazaki
    F Tanaka
    T Ito
    H Nishikawa
    A Osaki
    H Koyama
    T Suzuki
    [J]. British Journal of Cancer, 2009, 101 : 598 - 604
  • [8] Uracil-tegafur and tamoxifen versus cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in postoperative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study (vol 101, pg 598, 2009)
    Park, Y.
    Okamura, K.
    Mitsuyama, S.
    Saito, T.
    Koh, J.
    Kyono, S.
    Higaki, K.
    Ogita, M.
    Asaga, T.
    Inaji, H.
    Komichi, H.
    Kohno, N.
    Yamazaki, K.
    Tanaka, F.
    Ito, T.
    Nishikawa, H.
    Osaki, A.
    Koyama, H.
    Suzuki, T.
    [J]. BRITISH JOURNAL OF CANCER, 2009, 101 (06) : 1031 - 1031
  • [9] CHEMOTHERAPY VERSUS TAMOXIFEN VERSUS CHEMOTHERAPY PLUS TAMOXIFEN IN NODE-POSITIVE, ESTROGEN RECEPTOR-POSITIVE BREAST-CANCER PATIENTS - RESULTS OF A MULTICENTRIC ITALIAN STUDY
    BOCCARDO, F
    RUBAGOTTI, A
    BRUZZI, P
    CAPPELLINI, M
    ISOLA, G
    NENCI, I
    PIFFANELLI, A
    SCANNI, A
    SISMONDI, P
    SANTI, L
    GENTA, F
    SACCANI, F
    SASSI, M
    MALACARNE, P
    DONATI, D
    FARRIS, A
    CASTAGNETTA, L
    DICARLO, A
    TRAINA, A
    GALLETTO, L
    SMERIERI, F
    BUZZI, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (08) : 1310 - 1320
  • [10] Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group study
    Rivkin, SE
    Green, S
    OSullivan, J
    Cruz, AB
    Abeloff, MD
    Jewell, WR
    Costanzi, JJ
    Farrar, WB
    Osborne, CK
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) : 46 - 51
123